Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 17, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

A multimodal, β-amyloid-targeted contrast agent.

Sashiprabha M Vithanarachchi1, Matthew J Allen

  • 1Department of Chemistry, Wayne State University, 5101 Cass Avenue, Detroit, MI 48202, USA.

Chemical Communications (Cambridge, England)
|November 10, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single Molecule Eu<sup>2+/3+</sup> Complex Platform for Optical and Magnetic Resonance Imaging In Vivo.

Journal of the American Chemical Society·2026
Same author

Cyclen Tetra-Amide Ligands as a Privileged Class of Ligands for Studying Second-Sphere Coordination Environments.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Controlling the Kinetic and Electrochemical Properties of Eu<sup>II</sup>-Containing Complexes Using Peripheral Charges.

Inorganic chemistry·2026
Same author

Solution-Phase Electrochemical Characterization of Acyclic Complexes of Divalent Europium.

Inorganic chemistry·2025
Same author

Hypoxia Imaging as a Radiomics Signature in Tumors Using Novel <sup>19</sup>F-Eu-Based Contrast Agents for Magnetic Resonance Imaging.

bioRxiv : the preprint server for biology·2025
Same author

Use of image-guided robotic-assisted drilling for transcondylar screw placement in the canine humerus.

Veterinary surgery : VS·2025

Researchers developed a new imaging tool designed to detect protein clumps associated with Alzheimer's disease. This substance glows and alters magnetic signals when it binds to these specific deposits. It performs better than current standard medical imaging agents in laboratory tests. This innovation could improve how clinicians visualize brain pathology.

Area of Science:

  • Neuroimaging diagnostics within β-amyloid research
  • Molecular probe development in clinical chemistry

Background:

No prior work had resolved the limitations of current diagnostic tools for detecting specific protein plaques in neurodegenerative conditions. Existing contrast agents often lack the sensitivity required for early disease identification. This uncertainty drove the development of specialized molecules capable of targeting pathological aggregates. Prior research has shown that these protein deposits are hallmarks of cognitive decline. Scientists have long sought probes that combine multiple detection methods for enhanced accuracy. That gap motivated the creation of agents that provide both magnetic and optical signals. Conventional substances frequently fail to distinguish between healthy tissue and diseased regions effectively. This study addresses the need for improved molecular probes in medical imaging.

Purpose Of The Study:

The aim of the study is to develop and characterize a multimodal contrast agent specifically targeting protein aggregates. Researchers sought to create a probe that overcomes the limitations of current diagnostic substances. This project addresses the need for more sensitive tools in the detection of neurodegenerative markers. The team focused on synthesizing a molecule that provides both magnetic and optical signals. By combining these modalities, the authors intended to improve the visibility of pathological structures. This investigation explores how the agent interacts with its target to produce detectable changes. The motivation stems from the requirement for better contrast agents in medical imaging. The researchers aimed to demonstrate that their new design outperforms existing clinical standards in laboratory settings.

Keywords:
molecular imagingneurodegenerationfluorescence spectroscopymagnetic resonance

Frequently Asked Questions

The agent binds to protein aggregates, triggering shifts in both magnetic relaxation rates and light emission. This dual-response mechanism allows for the simultaneous detection of pathological structures using different imaging modalities. Researchers observed that these changes occur specifically upon interaction with the target material.

The probe utilizes a multimodal design, incorporating both magnetic resonance and fluorescence capabilities. This combination allows for versatile detection, unlike standard agents that typically rely on a single imaging modality. The researchers engineered the molecule to maximize signal output during laboratory assessments.

High sensitivity is necessary to distinguish pathological deposits from surrounding healthy tissue. The researchers propose that the agent's enhanced relaxivity is required to achieve better contrast than existing clinical standards. This property ensures that even small concentrations of the target are detectable.

Related Experiment Videos

Last Updated: May 17, 2026

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Main Methods:

Review Approach framing involves the systematic synthesis of laboratory data regarding the new molecular probe. Investigators utilized in vitro assays to evaluate the binding affinity of the synthesized substance. They conducted comparative analyses against a standard clinical imaging agent to determine relative efficacy. The team employed magnetic resonance spectroscopy to measure changes in relaxation rates. Fluorescence microscopy served as the primary tool for assessing optical emission properties. Researchers maintained controlled experimental conditions to ensure the reproducibility of all observed interactions. This design allowed for the precise characterization of the agent's physical and chemical behavior. The study focused on quantifying the performance of the probe in a simplified biological environment.

Main Results:

Key Findings From the Literature demonstrate that the new probe exhibits higher relaxivity than the clinically approved contrast agent. The substance successfully interacts with protein aggregates to induce measurable changes in relaxation rates. Researchers observed distinct fluorescence emission signals following the binding of the agent to its target. These results confirm the multimodal nature of the probe in laboratory testing. The data indicate that the agent provides a stronger signal response than existing diagnostic options. Quantitative measurements show clear differences in performance metrics between the new molecule and the standard alternative. The study highlights the effectiveness of the agent in identifying specific protein deposits. These findings establish a baseline for the potential application of the probe in diagnostic imaging.

Conclusions:

The synthesized probe demonstrates superior performance compared to standard clinical alternatives in laboratory settings. These findings suggest that the agent effectively binds to target aggregates to produce detectable signals. Synthesis and Implications framing indicates that dual-mode detection offers a robust approach for identifying pathological markers. Researchers observed significant variations in relaxation rates upon interaction with the intended targets. The data support the potential utility of this molecule for advanced diagnostic applications. Authors propose that the increased relaxivity provides a distinct advantage over currently available options. This work confirms that combining magnetic and optical properties enhances the visibility of specific protein structures. Future clinical utility remains a possibility based on these initial laboratory observations.

The study relies on in vitro data to evaluate the interaction between the probe and protein aggregates. This experimental approach allows for precise control over environmental conditions. Researchers used these controlled tests to quantify the performance metrics of the new substance.

The researchers measured the relaxation rate and fluorescence emission intensity of the probe. These metrics serve as indicators of successful binding to the target. The team compared these values against those of a clinically approved contrast agent to establish performance benchmarks.

The authors suggest that this multimodal approach could improve the detection of disease-related protein plaques. They propose that the agent offers a more sensitive alternative to current diagnostic tools. This implication highlights the potential for better imaging outcomes in clinical settings.